Expert Interview
Checking in with a prescriber of Eli Lilly's Olumiant (baricitinib) for the treatment of COVID-19.
Ticker(s): LLY-
Very comfortable speaking about antibiotic resistance frequently treats patient with bacterial infections and 10-15% of those patient have some type of antibiotic resistance
-
Hospitalist with Scripps Hospital and the University of Arizona
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
